Soft Loans and Grants

AbilityPharma shareholders include the venture capital firm Inveready, private investors and the founders of the company.

This company is capitalized by Innvierte, an investment program of CDTI, E.P.E.
The company has obtained grants and soft loans from high level public institutions:
  • NEBT grant from ACCIÓ, Government of Catalonia.
  • Technological Innovation Nuclei grant from ACCIÓ, Government of Catalonia.
  • PID soft loan from CDTI, Government of Spain.
  • Innoglobal from CDTI, Government of Spain.
  • Innocash from Fundación Genoma España, Government of Spain.
  • ENISA (National Innovation Company), Ministry of Industry, Energy and Tourism, Government of Spain.
  • Investment Readiness program from ACC1Ó, Government of Catalonia.
  • Torres-Quevedo grants from MINECO, Government of Spain.
  • International Talent grant from Biocat (Bioregion Catalonia), Government of Catalonia.
  • Inncorpora soft loan from the Ministry of Economy and Competitivity, Government of Spain.
  • Innpacto soft loan from the Ministry of Economy and Competitivity, Government of Spain.
  • Retos soft loan from the Ministry of Economy and Competitivity, Government of Spain.

Ability Pharmaceuticals participates in the projects"Development of new cancer therapies with high efficiency and specificity and low oral toxicity" and "Development of new financed by the call Retos-Colaboración del Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad, en el marco del Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016, with the dossier numbers: RTC-2014-1532-1 i RTC -2014-2589-1 respectively.

Ability Pharmaceuticals participates in the project  "New therapeutic approaches based on derivatives of essential fatty acids targeted to unmet needs in oncological and neurological diseases" funded by the INNPACTO call of the Spanish Research Program (MINECO) with dossier number  IPT- 2012-0614-010000.

The project called "Clinical Investigation of ABTL0812 in combination with chemotherapy in non-small cell lung cancer and identification of associated biomarkers", has been subsidized by the CDTI and supported by the Ministry of Economy, Industry and Competitiveness, under the file number INNO-20171061 .

Ability Pharmaceuticals has received grants for recruitment : Torres Quevedo (PTQ-11-04900, PTQ-12-05453), Inncorpora (INC-TU-2012-2617) and Emplea (EMP-2015-4578 -2015 and EMP-2015-4569).

The Ministry of Science, Innovation and Universities, within the State Plan for Scientific and Technical Research and Innovation 2013-2016, granted assistance to the project "NEW STRATEGIES TO INCREASE EFFECTIVENESS OF TREATMENTS WITH ABTL0812" led by Ability Pharmaceuticals SL with file number RTC -2017-6261-1.

This project has been funded by the Ministry of Science, Innovation and Universities within the RETOS-COLLABORATION Subprogram, Call 2017.

The project is co-financed by the European Union with the aim of promoting technological development, innovation and quality research.



Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info

Press Release

AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info

Press Release

AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info

Press Release

ABTL0812 shows potential against glioblastoma brain tumors + info

Press Release

AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info

Press Release

Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info

Press Release

AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info

Press Release

AbilityPharma Will Attend the ESMO Gynaecological Cancers Congress 2022 in Valencia + info

Press Release

AbilityPharma Will Attend BIO 2022 in San Diego as Part of the European Innovation Council (EIC) Delegation with a Booth in the European Pavilion + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police